Literature DB >> 26025498

[Sleep and sleep disorders in the elderly: Part 3: Restless legs syndrome].

H Frohnhofen1, J Schlitzer.   

Abstract

Restless legs syndrome (RLS) is a commonly occurring condition with a prevalence of approximately 10%. Women are more often affected than men. There is a primary and a secondary form. Secondary RLS is triggered by iron deficiency, severe renal insufficiency and many drugs and medications. The treatment for RLS is always symptomatic. In addition to treating associated diseases, dopaminergic therapy is paramount. Pharmacotherapy encompasses levodopa (L-dopa) and dopamine agonists, such as pramipexole, ropinirole and rotigotine. A serious complication of dopaminergic therapy is the so-called augmentation. In the case of insufficient efficacy, severe discomfort or augmentation, oxycodone/naloxone is now approved for the treatment of RLS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26025498     DOI: 10.1007/s00391-015-0901-4

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  47 in total

1.  A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients.

Authors:  M L Thorp; C D Morris; S P Bagby
Journal:  Am J Kidney Dis       Date:  2001-07       Impact factor: 8.860

Review 2.  Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome.

Authors:  Clete A Kushida
Journal:  Am J Med       Date:  2007-01       Impact factor: 4.965

3.  Epidemiology of restless legs symptoms in adults.

Authors:  B Phillips; T Young; L Finn; K Asher; W A Hening; C Purvis
Journal:  Arch Intern Med       Date:  2000-07-24

4.  "Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome.

Authors:  J Winkelmann; M Prager; R Lieb; H Pfister; B Spiegel; H-U Wittchen; F Holsboer; C Trenkwalder; A Ströhle
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

5.  Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease).

Authors:  Aaro V Salminen; Ville Rimpilä; Olli Polo
Journal:  Neurology       Date:  2014-04-30       Impact factor: 9.910

Review 6.  Clonazepam: benzodiazepine therapy for the restless legs syndrome.

Authors:  M S Joy
Journal:  ANNA J       Date:  1997-12

7.  Restless legs syndrome in end-stage renal disease.

Authors:  J W Winkelman; G M Chertow; J M Lazarus
Journal:  Am J Kidney Dis       Date:  1996-09       Impact factor: 8.860

8.  Comparison of pregabalin with pramipexole for restless legs syndrome.

Authors:  Richard P Allen; Crystal Chen; Diego Garcia-Borreguero; Olli Polo; Sarah DuBrava; Jeffrey Miceli; Lloyd Knapp; John W Winkelman
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

9.  A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.

Authors:  Ying Sun; Gert van Valkenhoef; Thomas Morel
Journal:  Curr Med Res Opin       Date:  2014-07-31       Impact factor: 2.580

10.  Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes.

Authors:  William Winlow
Journal:  Core Evid       Date:  2005-03-31
View more
  1 in total

Review 1.  Sleep in older adults and in subjects with dementia.

Authors:  Helmut Frohnhofen; Jeanina Schlitzer; Nikolaus Netzer
Journal:  Z Gerontol Geriatr       Date:  2017-07-18       Impact factor: 1.281

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.